Immuneering (NASDAQ:IMRX) Rating Reiterated by Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Immuneering (NASDAQ:IMRX - Free Report) in a research report report published on Friday morning, Benzinga reports. They currently have a $15.00 price target on the stock.

Several other research firms have also issued reports on IMRX. TD Cowen reissued a market perform rating on shares of Immuneering in a research report on Friday, March 15th. Jefferies Financial Group reaffirmed a hold rating and issued a $3.00 price target (down from $16.00) on shares of Immuneering in a report on Friday, March 15th. Guggenheim reiterated a neutral rating on shares of Immuneering in a research note on Thursday, March 14th. Chardan Capital cut their target price on Immuneering from $21.00 to $16.00 and set a buy rating for the company in a research note on Friday, March 15th. Finally, Oppenheimer reiterated an outperform rating and set a $25.00 price target on shares of Immuneering in a research report on Tuesday, March 5th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, Immuneering currently has a consensus rating of Moderate Buy and an average price target of $13.50.

Immuneering Stock Up 1.0 %

NASDAQ IMRX traded up $0.02 during trading hours on Friday, reaching $2.10. 257,603 shares of the company were exchanged, compared to its average volume of 579,141. The stock has a market capitalization of $61.49 million, a P/E ratio of -1.10 and a beta of -0.89. The business's 50 day simple moving average is $4.67 and its 200-day simple moving average is $5.96. Immuneering has a 1 year low of $1.90 and a 1 year high of $14.29.

Immuneering (NASDAQ:IMRX - Get Free Report) last released its earnings results on Friday, March 1st. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.06). As a group, sell-side analysts anticipate that Immuneering will post -1.89 earnings per share for the current year.

Insiders Place Their Bets

In other news, major shareholder Cormorant Asset Management, Lp sold 400,000 shares of Immuneering stock in a transaction on Monday, April 1st. The shares were sold at an average price of $2.90, for a total transaction of $1,160,000.00. Following the completion of the sale, the insider now directly owns 2,895,273 shares of the company's stock, valued at approximately $8,396,291.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, major shareholder Cormorant Asset Management, Lp sold 400,000 shares of the business's stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $2.90, for a total value of $1,160,000.00. Following the completion of the sale, the insider now owns 2,895,273 shares in the company, valued at approximately $8,396,291.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Benjamin J. Zeskind purchased 20,000 shares of Immuneering stock in a transaction on Tuesday, March 19th. The shares were acquired at an average price of $2.77 per share, for a total transaction of $55,400.00. Following the completion of the transaction, the chief executive officer now directly owns 2,281,852 shares of the company's stock, valued at $6,320,730.04. The disclosure for this purchase can be found here. Insiders purchased a total of 111,790 shares of company stock valued at $266,645 in the last quarter. Corporate insiders own 23.00% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of IMRX. Vanguard Group Inc. grew its position in Immuneering by 2.9% during the 4th quarter. Vanguard Group Inc. now owns 1,073,815 shares of the company's stock worth $7,893,000 after acquiring an additional 29,963 shares during the last quarter. Virtu Financial LLC bought a new stake in Immuneering during the 4th quarter valued at $84,000. Barclays PLC grew its holdings in Immuneering by 327.0% in the 4th quarter. Barclays PLC now owns 34,923 shares of the company's stock worth $257,000 after acquiring an additional 26,744 shares during the last quarter. Nuveen Asset Management LLC increased its position in shares of Immuneering by 8.6% in the fourth quarter. Nuveen Asset Management LLC now owns 44,049 shares of the company's stock valued at $324,000 after acquiring an additional 3,504 shares during the period. Finally, Oracle Alpha Inc. bought a new position in shares of Immuneering during the fourth quarter valued at about $87,000. 67.65% of the stock is owned by institutional investors.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.